The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status.
 
Takenori Takahata
No Relationships to Disclose
 
Satoshi Yuki
Speakers' Bureau - Chugai Pharma
 
Hiroshi Nakatsumi
No Relationships to Disclose
 
Kazuaki Harada
No Relationships to Disclose
 
Hiraku Fukushima
No Relationships to Disclose
 
Atsushi Sato
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Kato
No Relationships to Disclose
 
Takashi Meguro
No Relationships to Disclose
 
Michio Nakamura
No Relationships to Disclose
 
Nobuyuki Ehira
No Relationships to Disclose
 
Ichiro Iwanaga
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Kazunori Eto
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Yoshimitsu Kobayashi
No Relationships to Disclose
 
Osamu Muto
No Relationships to Disclose
 
Masakazu Abe
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Yoshito Komatsu
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma (Inst)